ACRS
HealthcareAclaris Therapeutics, Inc.
$2.65
$-0.23 (-7.99%)
Jan 5, 2026
Price History (1Y)
Analysis
Aclaris Therapeutics, Inc. is a biotechnology company operating within the healthcare sector. With a market capitalization of $287.11 million and revenue totaling $15.74 million, it is a relatively small player in its industry. The company employs 61 individuals. Financially, Aclaris Therapeutics has reported significant losses. Its net income was -$141,680,000 over the trailing twelve months, while EBITDA stood at -$65,738,000. The free cash flow was also negative at -$58,373,876. However, the company maintains a substantial amount of cash, totaling $95.91 million, and has a relatively low debt burden of $2.24 million. Aclaris Therapeutics' valuation metrics are somewhat volatile, with a forward P/E ratio of -4.67 and an EV/EBITDA ratio of -3.32. The price to book ratio is 2.39. Revenue growth over the past year has been negative at -24.1%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $287.11M
- P/E Ratio
- N/A
- 52-Week High
- $3.48
- 52-Week Low
- $1.05
- Avg Volume
- 1.29M
- Beta
- 0.43
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 61